In vivo application of Granulocyte-Macrophage Colony-stimulating Factor
enhances postoperative qualitative monocytic function by Lachmann, Gunnar et al.





International Journal of Medical Sciences 
2017; 14(4): 367-375. doi: 10.7150/ijms.18288 
Research Paper 
In vivo application of Granulocyte-Macrophage 
Colony-stimulating Factor enhances postoperative 
qualitative monocytic function 
Gunnar Lachmann1*, Johannes Kurth1*, Clarissa von Haefen1, Fatima Yuerek1, Klaus-Dieter Wernecke2, 
Claudia Spies1 
1. Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte and Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, 
Germany 
2. Sostana GmbH Berlin, Germany  
* These authors contributed equally to this work. 
 Corresponding author: Claudia Spies, Professor of Anesthesiology and Intensive Care Medicine, Department of Anesthesiology and Intensive Care Medicine, 
Campus Charité Mitte and Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. Phone: +49 30 
450 551 001; Fax: +49 30 450 551 909; Email: claudia.spies@charite.de 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2016.11.10; Accepted: 2017.01.30; Published: 2017.04.08 
Abstract 
BACKGROUND: Granulocyte macrophage colony-stimulating factor (GM-CSF) can be used as a 
potent stimulator for immune suppressed patients as defined by a decrease of human leukocyte 
antigen-D related expression on monocytes (mHLA-DR) after surgery. However, the exact role of 
GM-CSF on monocytic and T cell function is unclear. METHODS: In this retrospective randomized 
controlled trial (RCT) subgroup analysis, monocytic respectively T cell function and T cell subspecies of 
20 immune suppressed (i.e. mHLA-DR levels below 10,000 monoclonal antibodies (mAb) per cell at the 
first day after surgery) patients after esophageal or pancreatic resection were analyzed. Each 10 patients 
received either GM-CSF (250 μg/m²/d) or placebo for a maximum of three consecutive days if 
mHLA-DR levels remained below 10,000 mAb per cell. mHLA-DR and further parameters of immune 
function were measured preoperatively (od) until day 5 after surgery (pod5). Statistical analyses were 
performed using nonparametric statistical procedures. RESULTS: In multivariate analysis, mHLA-DR 
significantly differed between the groups (p < 0.001). mHLA-DR was increased on pod2 (p < 0.001) and 
pod3 (p = 0.002) after GM-CSF application. Tumor necrosis factor-α (TNF-α) release of 
lipopolysaccharide (LPS) stimulated monocytes multivariately significantly differed between the groups 
(p < 0.008) and was increased in the GM-CSF group on pod2 (p < 0.001) and pod3 (p = 0.046). 
Th17/regulatory T (Treg) cell ratio was higher after GM-CSF treatment on pod2 (p = 0.041). No 
differences were seen in lymphocytes and T helper cell (Th)1/Th2 specific cytokine production after T 
cell stimulation with Concanavalin (Con) A between the groups. CONCLUSIONS: Postoperative 
application of GM-CSF significantly enhanced qualitative monocytic function by increased mHLA-DR 
and TNF-α release after LPS stimulation and apparently enhanced Th17/Treg ratio. 
Clinical trial registered with www.controlled-trials.com (ISRCTN27114642) 05 December 2008. 
Key words: GM-CSF, HLA-DR, immune suppression, immune stimulation, monocytic function, T cell function, 
Th17/Treg ratio 
Background 
Monocytic human leukocyte antigen-D related 
(mHLA-DR) is crucial for antigen-presentation and 
reflects the functional state of immune competence 
since T cells are activated through recognition of 
antigens presented by mHLA-DR [1].  
Postoperative immune suppression is frequently 
observed after surgery due to surgical stress and 








mHLA-DR [2, 3]. Various further immune alterations 
occur after surgery [4], not at least an impairment of T 
cell function associated with an elevated risk for 
postoperative infections. A recent study of our 
research group aimed to stimulate postoperative 
immune function using GM-CSF and found an 
increase of mHLA-DR as well as a decrease of 
infection days after application of GM-CSF [5]. 
However, the exact role of GM-CSF on monocytic 
function and alterations of T cells after in vivo 
biomarker-guided postoperative immune stimulation 
is unclear. Therefore, monocytic and T cell function 
such as mHLA-DR, tumor necrosis factor alpha 
(TNF-α) after LPS stimulation, T cell counts, Th1/Th2 
specific cytokine production and the ratio of the 
number of Th17 cells to the number of Treg cells were 
studied after postoperative GM-CSF application.  
Patients and Methods 
Study Participants and Treatment 
This retrospective subgroup analysis is a further 
analysis of a previously published study [5] which 
studied further parameters of monocytic and T cell 
immune function between the GM-CSF and placebo 
group (Figure 1) that were determined in 10 patients 
of each study group (no selection of the patients, 
determination of further immune cells stopped after 
32 out of 61 patients of the bigger cohort due to 
economic reasons). 10 of the analyzed immune 
suppressed patients of each group after elective 
esophageal or pancreatic resection were treated for at 
least 24 hours with either GM-CSF (250 µg/m² body 
surface) or placebo in a double-blind fashion. If 
mHLA-DR levels remained below 10,000 mAb per cell 
on day 2 and day 3 after surgery (pod2 and pod3), the 
application of the study drugs was continued for a 
maximum of 72 hours (Figure 2). All patients received 
guideline-based anesthesiological and surgical 
treatment according to our standard operating 
procedures [6].  
This clinical trial was approved by the Ethics 
Committee of the Landesamt für Gesundheit und 
Soziales Berlin (LaGeSo), Germany (ref 
ZSEK15287/08) on September 01, 2008 and meets the 
requirements set out by the ICH-GCP, Declaration of 
Helsinki and the German Drug Law (AMG). Written 
informed consent was obtained. 
 
 
Figure 1. Consort diagram 
 
 
Figure 2. Trial Flowchart 





Measurement of parameters of immune 
function  
Blood samples were drawn from od until pod5 
and intraoperative parameters (blood loss, blood 
glucose, blood lactate, systolic blood pressure and 
surgical time) were documented. mHLA-DR and 
further parameters of immune function were 
measured from od until pod5. Expression of 
mHLA-DR on monocytes was determined by flow 
cytometry using a highly standardized quantitative 
assay as described earlier [7]. For determination of 
soluble mediators, ethylenediaminetetraacetic acid 
(EDTA) and heparin plasma samples were collected 
and stored at -80°C until assayed. Plasma levels of C 
reactive protein (CRP) were measured using an 
immunoturbidometric assay (Roche Diagnostics). 
Procalcitonin (PCT) concentration was measured 
using a commercial immunoluminometric assay 
(Brahms, Hennigsdorf, Germany). All immunologic 
parameters were analyzed in collaboration with the 
Institute of Medical Immunology and 
Berlin-Brandenburg Center for Regenerative 
Therapies (BCRT), Charité – Universitätsmedizin 
Berlin, Berlin, Germany. White blood cell differential 
count was measured on a standard hematology 
analyzer (Sysmex). For flow cytometry analysis, the 
following fluorescence-labeled mouse anti-human 
monoclonal antibodies (BD Biosciences, Heidelberg, 
Germany) were used: cluster of differentiation (CD)2, 
CD4 and CD16 fluorescein isothiocyanate (FITC); 
CD3, CD19 phycoerythrin (PE); CD45, CD4 peridinin 
chlorophyll (PerCP); CD8 allophycocyanine (APC). 
Lymphocyte subpopulations were identified using 
following antibody combinations: CD45 for 
leukocytes, CD3+ for T lymphocytes, CD3+CD4+ for 
Th cells, CD3+CD8+ for cytotoxic T cells, CD2+ 
CD3-CD16+ for natural killer (NK) cells, CD19+ for B 
lymphocytes. Cell phenotyping was performed by 
flow cytometry/fluorescence-activated cell sorting 
(FACS) on a FACSCalibur ™ using CELLQuest™ 
Software (BD Biosciences).  
Stimulation of whole blood cultures with LPS 
and Con A  
For analysis of ex vivo endotoxin-induced 
cytokine synthesis, heparinized blood was diluted 
1:10 with RPMI 1640 medium (Biochrom KG, Berlin, 
Germany) and stimulated with endotoxin (500 
pg/mL; Milenia Ex Vivo Whole Blood Stimulation kit, 
Milenia Biotec, Giessen, Germany) at 37°C and 5% 
CO2. TNF-α, and interleukin (IL)-10 secretion was 
measured in culture supernatants after 4 and 24 
hours, respectively. Con A-induced lymphocytic 
interferon (IFN)-γ, TNF-α, IL-2, IL-4, IL-5 and IL-10 
secretion was analyzed in 24 hours stimulated whole 
blood sample supernatants by Cytometric Bead Array 
(BD Biosciences). 
Flow cytometric analysis of Treg and Th17 
cells 
Th17 and Treg cell concentrations were analyzed 
at the research laboratory of the Department of 
Anesthesiology and Intensive Care Medicine, 
Campus Charité Mitte and Campus 
Virchow-Klinikum, Charité – Universitätsmedizin 
Berlin using four-color flow cytometry on a 
FACSCanto II™ and FACS™DIVA Software (BD 
Biosciences). For the quantification of Treg cells, the 
following antibodies were added to EDTA-blood 
samples: CD4PerCP, CD3 pacific blue for identifying 
Th cells and CD 25 APC, CD 127 PE to extract Treg 
cells (low CD 127, high CD 25). For the analysis of 
Th17 cells, peripheral mononuclear cells (PBMC) were 
separated from citrate anticoagulated blood. After 
counting the cells, cytokine production was 
stimulated for two hours using phorbol-12-myristate- 
13-acetate (PMA) and inomycin (Sigma Aldrich, 
Taufkirchen, Germany). GolgiStop™ (BD Biosciences) 
was then added for further 2 hours to ensure 
intracellular accumulation of cytokines before 
staining the superficial antigens CD3 and CD8 using 
CD3 pacific blue and CD8 APC. For determination of 
intracellular IL-17, cells were fixated and 
permeabilized using FACS™Fix/Perm Solution (BD 
Biosciences) and stained using IL-17 PE. All used 
antibodies were achieved from BD Biosciences. 
Statistical analysis 
Data were expressed according to their scaling as 
arithmetic mean ± standard deviation (SD), median 
[25%, 75% quartiles], or frequencies [%], respectively. 
After exploratory data analysis, all tests were 
accomplished by means of non-parametric exact 
statistical tests. Basic patient characteristics and post 
intervention characteristics were evaluated for group 
differences using the exact Mann-Whitney test for 
continuous variables and Fisher’s exact test for 
categorical variables. Changes in interesting clinical 
outcomes with respect to time were analyzed using 
multivariate nonparametric analysis of longitudinal 
data in a two-factorial design (1st factor: groups, 2nd 
factor: repetitions in time) (nonparametric MANOVA 
for repeated measures). Therefore, we compared all 
time points simultaneously on the corresponding 
response curves. This analysis proves hypotheses 
about group differences between GM-CSF and 
placebo, systemic changes in time, and interactions 
between groups and time, as well as tests for systemic 
time changes for every treatment separately. In cases 
of relevant differences at baseline, a multivariate 




nonparametric analysis of covariance (MANCOVA) 
for repeated measures with the baseline as covariate 
was applied. 
After such global tests over time domain, 
differences in immune cells and cytokines were 
ascertained with univariate post-hoc analyses to 
detect specific differences with respect to groups for 
fixed times (exact Mann-Whitney tests). A two-tailed 
p-value < 0.05 was considered statistically significant. 
All tests should be understood as constituting 
exploratory data analysis, such that no adjustments 
for multiple testing have been made. Numerical 
calculations were performed with IBM© SPSS© 
Statistics, Version 23, and SAS™ (Version 9.1) 
software and The R Project for Statistical Computing, 
Version 3.0.2 (2013-09-25), Copyright (C) 2013 The R 
Foundation for Statistical Computing. 
Results 
Study population and groups 
Basic patient characteristics, intraoperative und 
pre-interventional parameters did not differ between 
the groups (Table 1). In the GM-CSF group, all 
patients received study medication on pod1, one 
patient on pod2 and two patients on pod3 since 
mHLA-DR was < 10,000 mAb per cell in these 
patients. In the placebo group, all patients were 
treated on pod1 and on pod2 and nine patients on pod3.  
GM-CSF significantly enhanced qualitative 
monocytic function 
Our research group could already show that 
postoperative application of GM-CSF could increase 
mHLA-DR [5]. Our subanalyses now showed the 
same results: Nonparametric MANOVA for repeated 
measures regarding mHLA-DR showed significant 
differences over time between the groups (p < 0.001). 
mHLA-DR significantly decreased after surgery in all 
20 patients (p < 0.001 between od and pod1). 
mHLA-DR was increased on pod2 (p < 0.001), pod3 (p 
= 0.002) and slightly on pod4 (p = 0.052) after GM-CSF 
application (Figure 3). TNF-α release of LPS 
stimulated monocytes significantly differed between 
the groups (p < 0.008) in multivariate MANOVA and 
was increased in the GM-CSF group on pod2 (p < 
0.001) and pod3 (p = 0.046) (Figure 4). IL-10 release of 
stimulated monocytes and absolute monocyte counts 
showed no significant differences (data not shown). 
GM-CSF enhanced the ratio of Th17/Treg cells 
Univariate testing revealed no significant 
differences between the groups for the concentrations 
of Th17 and Treg cells, although we found a tendency 
for elevated Th17 concentration in GM-CSF treated 
patients on pod2 (p = 0.05; Table 2). However, 
multivariate nonparametric analysis of covariance for 
repeated measures with the baseline as covariate 
showed significant differences between the groups for 
Treg cells over time (p = 0.036). Furthermore, 
Th17/Treg ratio on pod2 (p = 0.041) was significantly 
higher in patients treated with GM-CSF (Figure 5). 
 
 
Table 1. Basic patient characteristics and pre-interventional 
course. 
 Placebo  
(n = 10) 
GM-CSF  
(n = 10) 
p-value 
Age [years] 62 (55-69) 64 (54-69) 0.796 
Gender male/female [n] 7/3 9/1 0.582 
Body Mass Index [kg/m²] 25.5 (24.2-27.5) 25.8 (23.3-28.0) 0.912 
Pancreatic/esophageal resection [n] 6/4 4/6 0.656 
ASA score II/III [n] 7/3 5/5 0.650 
smokers/non-smokers [n] 4/6 3/7 1.000 
AUDIT score 3 (0-6) 4 (2-4) 0.708 
metabolic equivalent (MET) 
<4/4-10/>10 
0/8/2 0/10/0 0.474 
NRS at rest dBs  1 (0-3) 0 (0-1) 0.166 
NRS at rest pod1  2 (0-3) 3 (0-5) 0.055 
NRS during movement pod1  5 (0-7) 5 (3-7) 0.416 
surgical time [min] 308 (280-378) 346 (272-390) 0.529 
blood loss [mL] 600 (313-950) 650 (575-875) 0.696 
blood glucose [mg/dL] 127 (122-142) 138 (120-145) 0.739 
blood lactate [mmol/L] (max.) 1.0 (0.8-1.3) 1.1 (0.9-1.7) 0.529 
systolic blood pressure [mmHg] 113 (109-117) 116 (112-126) 0.190 
APACHE II score on admission to 
ICU 
12 (9-16) 12 (11-13) 0.500 
SAPS II score on admission to ICU 22 (12-27) 28 (17-30) 0.097 
SOFA score on admission to ICU 2 (1-4) 1 (0-4) 1.000 
TISS 28 score on admission to ICU 32 (27-36) 29 (23-36) 0.169 
Continuous quantities in median (25%-75% percentiles), frequencies with n (%); NRS, 
Numeric Rating Scale; dBs, day before surgery; pod1, day 1 after surgery; ASA, American 
Society of Anesthesiologists; AUDIT score, Alcohol Use Disorders Identification Test; 
PONV, postoperative nausea and vomiting; APACHE, Acute Physiology and Chronic 
Health Evaluation; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ 




Table 2. Treg and Th17 cells. 
 Placebo  
(n = 10) 
GM-CSF  
(n = 10) 
p-value 






 od 0.9 (0.6-1.7) 0.8 (0.6-1.9) 0.970 
pod1 1.5 (1.0-2.5) 1.6 (1.1-2.6) 0.970 
pod2 0.8 (0.7-1.7) 1.7 (1.2-2.9) 0.050 
pod3 1.3 (0.6-2.3) 1.9 (1.5-2.4) 0.227 
pod4 1.5 (0.8-2.0) 1.3 (1.1-2.6) 0.479 
 pod5 1.2 (1.0-2.0) 1.7 (1.0-3.0) 0.289 






 od 5.6 (4.8-6.1) 5.3 (3.1-7.0) 0.940 
pod1 5.7 (5.0-8.4) 5.6 (3.2-7.6) 0.579 
pod2 7.9 (5.1-8.6) 6.1 (4.5-7.8) 0.273 
pod3 8.1 (6.0-8.9) 5.7 (4.7-7.2) 0.140 
pod4 7.2 (5.6-9.1) 5.2 (4.5-7.4) 0.130 
 pod5 6.1 (5.8-10.1) 5.7 (4.6-8.0) 0.287 
Continuous quantities in median (25%-75% percentiles); od, day of surgery before surgery; 
pod, day after surgery 
 
 






Figure 3. mHLA-DR from day of surgery before surgery (od) until day 5 after surgery (pod5) between the groups. Nonparametric MANOVA for repeated measures 
regarding mHLA-DR showed significant differences over time between the groups (p < 0.001). mHLA-DR significantly decreased after surgery in all 20 patients (p < 
0.001 between od and pod1). mHLA-DR significantly increased on pod2 (***p < 0.001), pod3 (**p = 0.002) and slightly on pod4 (p = 0.052) after GM-CSF application. 
 
 
Figure 4. TNF-α release of LPS stimulated monocytes from day of surgery before surgery (od) until day 5 after surgery (pod5) between the groups. TNF-α significantly 
differed between the groups (p < 0.008) in multivariate MANOVA and was increased on pod2 (***p < 0.001) and pod3 (*p = 0.046) after stimulation with GM-CSF. 





GM-CSF did not change Th1/Th2 specific 
cytokine production 
After stimulation of whole blood cultures for 24 
h with Con A, the cytokines for Th1 and Th2 
responsiveness IL-4, IL-5, IL-10, IFN-γ and TNF-α 
showed no differences between the groups (Table 3). 
Noteworthy, IL-2 slightly increased after GM-CSF 
application on pod2 (p = 0.073). 
 
Table 3. Th1/Th2 specific cytokine production. 
 Placebo  
(n = 10) 
GM-CSF  
(n = 10) 
p-value 
IL-2 [pg/mL]    
 od 152 (146-271) 223 (100-481) 1.000 
pod1 121 (81-172) 231 (90-354) 0.181 
pod2 110 (79-216) 190 (117-414) 0.073 
pod3 137 (79-199) 245 (112-467) 0.138 
pod4 152 (133-207) 176 (77-505) 0.699 
pod5 168 (109-223) 233 (123-415) 0.366 
IL-4 [pg/mL]    
 od 3.0 (2.0-12.0) 2.5 (2.0-9.8) 0.731 
pod1 7.0 (2.0-12.0) 6.5 (2.0-28.8) 1.000 
pod2 4.0 (2.0-11.0) 8.0 (3.5-21.3) 0.295 
pod3 7.0 (2.0-13.0) 8.5 (5.0-19.0) 0.731 
pod4 8.0 (5.3-16.3) 10.5 (2.0-17.3) 1.000 
pod5 2.0 (2.0-9.0) 9.0 (4.3-14.3) 0.234 
IL-5 [pg/mL]    
 od 6.0 (2.0-26.0) 23.5 (2.0-33.8) 0.628 
pod1 9.0 (4.0-65.0) 19.5 (5.5-69.3) 0.628 
pod2 5.0 (3.0-31.0) 11.0 (2.8-29.8) 0.836 
pod3 11.0 (7.0-20.0) 26.5 (2.0-59.8) 0.628 
pod4 11.0 (5.3-28.0) 15.0 (3.5-38.8) 1.000 
pod5 7.0 (4.0-17.0) 14.0 (7.3-48.3) 0.534 
IL-10 [pg/mL]    
 od 71 (34-91) 90 (37-130) 0.731 
pod1 80 (46-136) 86 (59-131) 0.731 
pod2 48 (40-104) 86 (39-148) 0.628 
pod3 56 (32-72) 75 (51-125) 0.445 
pod4 47 (32-115) 100 (50-112) 0.394 
pod5 39 (30-67) 89 (58-143) 0.101 
IFN-γ [pg/mL]    
 od 757 (275-1,784) 1,553 (721-3,594) 0.295 
pod1 296 (95-1,045) 509 (166-719) 1.000 
pod2 259 (163-1,084) 587 (191-913) 1.000 
pod3 374 (88-1,237) 765 (491-986) 0.295 
pod4 318 (230-1,719) 509 (281-1,462) 0.589 
 pod5 345 (43-1,874) 724 (289-1,268) 0.628 
TNF-α [pg/mL]    
 od 378 (107-468) 571 (220-710) 0.234 
pod1 110 (18-202) 167 (82-272) 0.628 
pod2 70 (39-105) 162 (31-242) 0.534 
pod3 116 (87-154) 167 (117-245) 0.366 
pod4 152 (78-370) 116 (78-292) 0.818 
 pod5 209 (29-573) 193 (155-274) 1.000 
Continuous quantities in median (25%-75% percentiles); od, day of surgery before surgery; 
pod, day after surgery 
 
Impact of GM-CSF on inflammatory mediators 
and peripheral blood leukocytes  
As shown in Table 4, there were no significant 
changes concerning the total counts of granulocytes, 
monocytes and lymphocytes between the groups. 
Slight increases were seen for total leukocyte (p = 
0.063) and granulocyte count (p = 0.075) on pod2 after 
GM-CSF application. Lymphocyte subspecies such as 
NK cells, CD3+, CD4+ and CD8+ T lymphocytes did 
not differ between the groups (Table 5). However, B 
lymphocytes also showed slight increases in the 
GM-CSF group on pod4 (p = 0.052) and pod5 (p = 
0.053). CRP and PCT did not differ between the 
groups either (data not shown).  
 
Table 4. Peripheral blood leukocytes. 
 Placebo  
(n = 10) 
GM-CSF  
(n = 10) 
p-value 
Leukocytes [1/nL]    
 od 5.7 (4.0-7.2) 5.7 (5.0-7.5) 0.481 
pod1 10.0 (9.3-13.5) 8.1 (7.2-13.0) 0.315 
pod2 11.5 (8.2-12.6) 16.7 (9.0-20.5) 0.063 
pod3 9.4 (7.4-11.4) 11.2 (6.5-13.7) 0.912 
pod4 9.3 (7.0-11.7) 10.7 (8.0-13.0) 0.684 
pod5 10.6 (6.2-11.9) 11.8 (7.4-15.3) 0.447 
Granulocytes [1/nL]    
  
 od 
3.4 (2.7-3.9) 3.8 (2.6-5.6) 0.631 
pod1 8.7 (7.8-10.6) 6.6 (5.8-11.0) 0.393 
pod2 9.9 (7.4-10.4) 15.1 (7.6-18.4) 0.075 
pod3 7.6 (6.3-9.4) 9.5 (5.4-11.6) 0.853 
pod4 7.5 (6.1-9.7) 7.6 (5.3-9.7) 0.853 
pod5 7.6 (4.6-9.8) 9.6 (5.6-12.4) 0.278 
Monocytes [1/nL]    
 od 0.49 (0.41-0.67) 0.60 (0.52-0.76) 0.105 
pod1 0.73 (0.62-1.25) 0.75 (0.62-1.11) 0.529 
pod2 0.73 (0.52-1.02) 0.89 (0.64-1.22) 0.447 
pod3 0.67 (0.55-0.88) 0.75 (0.61-0.93) 0.123 
pod4 0.77 (0.60-1.18) 0.87 (0.78-1.09) 0.143 
pod5 1.06 (0.68-1.50) 1.25 (0.92-1.72) 0.829 
Lymphocytes [1/nL]    
 
 od 
1.00 (0.77-2.52) 1.36 (1.20-1.72) 0.796 
pod1 0.86 (0.55-1.05) 0.74 (0.60-0.82) 0.393 
pod2 0.74 (0.55-1.36) 0.76 (0.69-0.82) 0.912 
pod3 0.64 (0.47-1.20) 0.77 (0.67-1.04) 0.579 
pod4 0.54 (0.39-1.10) 0.76 (0.61-1.21) 0.247 
pod5 0.66 (0.42-1.37) 0.98 (0.67-1,32) 0.278 
Continuous quantities in median (25%-75% percentiles); od, day of surgery before surgery; 




The major finding of this subgroup analysis of 
our previously published study is that postoperative 
GM-CSF treatment enhanced monocytic function 
(mHLA-DR and ability of TNF-α release) but not the 
absolute count of monocytes. Furthermore, 
Th17/Treg ratio was increased. To the best of our 
knowledge, no other studies investigated monocytic 
function and the balance between Th17 and Treg cells 
after postoperative in vivo biomarker-guided 
application of GM-CSF in immune compromised 
patients. 





Figure 5. Th17/Treg ratio from day of surgery before surgery (od) until day 5 
after surgery (pod5) between the groups. Th17/Treg ratio significantly increased 
on pod2 (*p = 0.041) after stimulation with GM-CSF. 
Table 5. Lymphocyte subspecies. 
 Placebo  
(n = 10) 
GM-CSF  
(n = 10) 
p-value 
B lymphocytes [1/nL]    
 od 0.08 (0.04-0.26) 0.11 (0.08-0.13) 0.529 
pod1 0.09 (0.04-0.15) 0.07 (0.06-0.10) 0.796 
pod2 0.08 (0.04-0.14) 0.11 (0.08-0.12) 0.218 
pod3 0.07 (0.04-0.12) 0.11 (0.10-0.11) 0.105 
pod4 0.06 (0.03-0.10) 0.10 (0.08-0.14) 0.052 
pod5 0.06 (0.04-0.11) 0.13 (0.09-0.19) 0.053 
CD3+ T lymphocytes [1/nL]    
 od 0.79 (0.61-2.20) 1.10 (0.91-1.33) 0.796 
pod1 0.61 (0.39-0.87) 0.55 (0.43-0.69) 0.739 
pod2 0.62 (0.42-1.02) 0.59 (0.52-0.63) 0.529 
pod3 0.52 (0.33-0.97) 0.60 (0.50-0.78) 0.796 
pod4 0.45 (0.31-1.13) 0.58 (0.48-0.92) 0.529 
pod5 0.49 (0.32-1.09) 0.77 (0.51-1.00) 0.315 
CD4+ T lymphocytes [1/nL]    
 od 0.44 (0.25-1.01) 0.73 (0.47-0.80) 0.684 
pod1 0.37 (0.20-0.47) 0.32 (0.22-0.42) 0.684 
pod2 0.34 (0.18-0.45) 0.35 (0.25-0.43) 0.739 
pod3 0.25 (0.20-0.54) 0.43 (0.31-0.49) 0.684 
pod4 0.28 (0.17-0.68) 0.41 (0.26-0.52) 0.684 
pod5 0.28 (0.21-0.75) 0.48 (0.31-0.65) 0.356 
CD8+ T lymphocytes [1/nL]    
 od 0.25 (0.17-0.43) 0.30 (0.20-0.51) 1.000 
pod1 0.19 (0.10-0.35) 0.16 (0.10-0.24) 0.579 
pod2 0.16 (0.09-0.30) 0.17 (0.13-0.27) 0.796 
pod3 0.14 (0.09-0.28) 0.17 (0.12-0.27) 1.000 
pod4 0.14 (0.06-0.61) 0.18 (0.11-0.35) 0.739 
pod5 0.14 (0.08-0.42) 0.22 (0.11-0.42) 0.780 
NK cells [1/nL]    
 od 0.15 (0.10-0.20) 0.18 (0.09-0.27) 0.353 
pod1 0.11 (0.09-0.16) 0.10 (0.04-0.13) 0.579 
pod2 0.09 (0.06-0.13) 0.12 (0.05-0.12) 0.739 
pod3 0.06 (0.04-0.08) 0.09 (0.05-0.11) 0.190 
pod4 0.07 (0.05-0.11) 0.08 (0.06-0.12) 0.218 
pod5 0.09 (0.05-0.14) 0.11 (0.06-0.15) 0.720 
Continuous quantities in median (25%-75% percentiles); od, day of surgery before surgery; 
pod, day after surgery 
 
In general, GM-CSF is often used in neutropenic 
patients resulting in mobilization of myeloid cells and 
of those an increasing survival and activation [8]. On 
monocytes, 190 genes are upregulated and 212 genes 
are downregulated after GM-CSF application [9]. A 
role more as an immune modulator than a growth 
factor is assumed [10]. During the last decade, studies 
focused on immune stimulation in immune 
compromised patients [11-13]. Nierhaus et al. [14] as 
well as Meisel et al. [11] were the first who stratified 
severe septic patients as immune compromised using 
mHLA-DR expression as biomarker threshold for in 
vivo GM-CSF immune stimulation. Both studies could 
increase mHLA-DR whereas Meisel at al. could also 
decrease the time of ventilation and shorten the ICU 
and hospital stay.  
Meisel et al. [11] further studied immune cells 
and cytokines and similar to our results they found an 
increase in stimulated monocytic TNF-α. However, 
main differences to our results were seen in increasing 
monocytes and T lymphocytes in their analyses. We 
saw stable monocyte and T lymphocyte count. 
Nonetheless, monocytic function was restored in both 
studies as mHLA-DR and TNF-α of stimulated 
monocytes increased. Most likely, differences in T 
cells between both studies are due to the study design: 
Meisel et al. stimulated for 8 days whereas we 
stimulated at least for one but maximum for 3 days. 
Thus, interactions between monocytes and T cells 
seem to be more pronounced after long-term 
stimulation. However, we already saw interactions on 
day 2 after surgery by an increased Th17/Treg ratio. 
Surprisingly, we did not see increasing monocytes 
after GM-CSF stimulation. Though GM-CSF is 
capable of generating both cells from bone marrow 
[15, 16], postoperative increases of monocytes after 
GM-CSF application failed to materialize. In contrast 
to Meisel at el., Nierhaus et al. [14] found no increase 
in monocytes after GM-CSF treatment in severe septic 
patients. Inferentially, contradiction persists about 
behavior of monocytes after stimulation during severe 
sepsis. The underlying cause of the absences of 
increasing monocytes in our study is unclear. One 
explanation might be a lack of progenitor cells in the 
bone marrow due to a previous release 
intraoperatively caused by surgical stress and trauma. 
The major effect of GM-CSF therefore seems to be 
more the enhanced function than the absolute count 
of monocytes, i.e. GM-CSF enhanced qualitative but 
not quantitative monocytic function.  
GM-CSF did not change the amount of 
peripheral blood leukocytes and Th1/Th2 specific 
cytokine production after Con A stimulation. 
Lymphocytes and NK cells generally do not express 




GM-CSF receptors, thus could not directly be 
influenced by GM-CSF [17]. Increasing lymphocyte 
counts after GM-CSF application by Meisel et al. [11] 
and an increased Th17/Treg ratio in our study 
indicate that GM-CSF might have indirect effects on 
lymphocytes, likely through interactions with 
monocytes [10, 18]. Immune stimulatory effects of 
GM-CSF thus covers far more than monocytic 
function. We found an increased Th17/Treg ratio in 
patients receiving GM-CSF but only a tendencially 
increased Th17 concentration occurred, which is likely 
due to the small sample size. Th17 cells represent a 
pro-inflammation, whereas Treg cells have an 
anti-inflammatory effect. Their developmental 
pathways are reciprocally interconnected and there is 
an important plasticity between Th17 and Treg cells 
[19, 20]. Changes of the Th17/Treg ratio during 
surgery may contribute to an imbalance between pro- 
and anti-inflammatory immune response and factors 
recovering the balance between Th17 and Treg cells 
may generate potential therapeutic targets. Major 
interest of further research could be NK and cytotoxic 
T cell function after GM-CSF application, particularly 
after surgery when immune function of these cells is 
essential to avoid infections, cancer metastases and 
recurrence.  
In our previous published study [5] we found a 
reduced duration of infections after postoperative 
GM-CSF application. We previously postulated that 
this reduction is due to the increase of mHLA-DR and 
associated with a restored monocytic function. In the 
current analyses, we could reinforce this assumption: 
we have additionally seen increased TNF-α levels 
after monocytic stimulation and, particularly 
noteworthy an increased Th17/Treg ratio. This 
restoration most likely shortened the duration of 
infection but did not prevent patients from 
developing infections. Restoration of monocytic 
function is of major relevance as sepsis is 
characterized by a reduced ability of monocytes to 
secrete pro-inflammatory cytokines, and an impaired 
antigen presentation by mHLA-DR [8]. Interestingly, 
effects of GM-CSF lasted only for time of application 
and declined after stop. The exact mechanism is 
unclear - perhaps monocytes remain in an immune 
suppressive state being just boostered and declining 
to initial values.  
This study reveals several limitations. First of all, 
it is a retrospective subgroup analysis. Second, study 
drugs were administered only for a maximum of 
consecutive 3 days. The effect of longer duration of 
therapy on monocytes and immunity is unclear. 
Third, we analyzed only a small sample size of 10 
patients in each group. Hence, some results might 
possibly be not significant but show a tendency. 
Fourth, we analyzed patients only until pod5. The 
impact of GM-CSF application on immune function 
after this time is unclear. Finally, the threshold level 
for mHLA-DR (we had ≤ 10,000 mAb/cell) used to 
stratify patients with severe surgery-induced 
immunosuppression is unclear. Studies suggest that 
values between 5,000 and 10,000 mAb/cell are an 
indicator of severely impaired immune function in 
critically ill patients [7, 11, 21].  
Conclusions 
Postoperative application of GM-CSF 
significantly enhanced qualitative but not quantitative 
monocytic function seen in an increased expression of 
mHLA-DR and TNF-α release after LPS stimulation 
whereas counts of monocytes did not increase. 
Furthermore, we found an increased Th17/Treg ratio 
after GM-CSF application. The balance of Th17 and 
Treg cells is regarded as a key factor in immune 
homeostasis. These findings should be the subject of 
further studies to determine whether Th17/Treg may 
serve as a potential therapeutic target to manage 
immune suppressed patients. 
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